StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant (VRX) PT Cut to $38 at BMO Capital
June 8, 2016 6:27 AM
BMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
BTIG Sees Valeant's (VRX) Growth Plan Taking Longer than Expected to Implement; Affirms at 'Neutral' (WBA)
June 8, 2016 2:06 PM
Valeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies
June 8, 2016 8:50 AM
Valeant (VRX) PT Cut to $33 at RBC Capital
June 8, 2016 7:07 AM
Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim
June 8, 2016 6:57 AM
Form 10-Q Valeant Pharmaceuticals For: Mar 31
June 7, 2016 5:18 PM
Valeant Pharma (VRX) Will Conduct Webcast of Annual Shareholders Meeting on June 14th
June 7, 2016 5:08 PM
Valeant CEO cuts outlook for 'distracted' company, shares plunge
June 7, 2016 4:45 PM
Valeant (VRX) Product Commentary 'Concerning', Piper Jaffray Says; PT Set at $19
June 7, 2016 11:44 AM
Valeant Pharma (VRX) Moves Sharply Off Morning Lows
June 7, 2016 11:29 AM
Valeant Pharma (VRX) EBITDA Guidance Just Above Maintenance Covenants - Evercore ISI's Raffat
June 7, 2016 8:06 AM
Valeant Pharma (VRX) Misses Q1 EPS by 10c; Cuts FY16 Outlook
June 7, 2016 6:02 AM
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM
